HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Lowers Price Target to $87

Benzinga · 01/07 12:12
HC Wainwright & Co. analyst Andrew Fein maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and lowers the price target from $90 to $87.